These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 17329169)
1. Overview of Infections in the Immunocompromised Host. Dropulic LK; Lederman HM Microbiol Spectr; 2016 Aug; 4(4):. PubMed ID: 27726779 [TBL] [Abstract][Full Text] [Related]
2. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Rose-John S; Winthrop K; Calabrese L Nat Rev Rheumatol; 2017 Jul; 13(7):399-409. PubMed ID: 28615731 [TBL] [Abstract][Full Text] [Related]
3. Update on the use of rituximab for intractable rheumatoid arthritis. Looney RJ Open Access Rheumatol; 2009; 1():83-94. PubMed ID: 27789983 [TBL] [Abstract][Full Text] [Related]
4. A novel assay to measure B cell responses to keyhole limpet haemocyanin vaccination in healthy volunteers and subjects with systemic lupus erythematosus. Ferbas J; Belouski SS; Horner M; Kaliyaperumal A; Chen L; Boyce M; Colaço CB; McHugh N; Quick V; Nicholl RJ; Siu G; Chung J Br J Clin Pharmacol; 2013 Aug; 76(2):188-202. PubMed ID: 23731388 [TBL] [Abstract][Full Text] [Related]
5. Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination. Westerink MA; Schroeder HW; Nahm MH Aging Dis; 2012 Feb; 3(1):51-67. PubMed ID: 22500271 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Benson JM; Sachs CW; Treacy G; Zhou H; Pendley CE; Brodmerkel CM; Shankar G; Mascelli MA Nat Biotechnol; 2011 Jul; 29(7):615-24. PubMed ID: 21747388 [TBL] [Abstract][Full Text] [Related]
7. Good and bad memories following rituximab therapy. St Clair EW Arthritis Rheum; 2010 Jan; 62(1):1-5. PubMed ID: 20039422 [No Abstract] [Full Text] [Related]
8. The effects of rituximab on immunocompetency in patients with autoimmune disease. Looney RJ; Srinivasan R; Calabrese LH Arthritis Rheum; 2008 Jan; 58(1):5-14. PubMed ID: 18163518 [No Abstract] [Full Text] [Related]
9. Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. Looney RJ; Diamond B; Holers VM; Levesque MC; Moreland L; Nahm MH; St Clair EW; Clin Immunol; 2007 Jun; 123(3):235-43. PubMed ID: 17329169 [TBL] [Abstract][Full Text] [Related]
10. Screening and Monitoring for Infectious Complications When Immunosuppressive Agents Are Studied in the Treatment of Autoimmune Disorders. Loechelt BJ; Green M; Gottlieb PA; Blumberg E; Weinberg A; Quinlan S; Baden LR; J Pediatric Infect Dis Soc; 2015 Sep; 4(3):198-204. PubMed ID: 26336066 [TBL] [Abstract][Full Text] [Related]
11. Immune monitoring to predict the development of infections after immunosuppression for solid organ transplantation and autoimmune diseases. Carbone J; Lanio N; Gallego A; Sarmiento E Curr Drug Saf; 2008 May; 3(2):91-9. PubMed ID: 18690987 [TBL] [Abstract][Full Text] [Related]